Dr. Babcock has 18 years of pharmaceutical industry experience leading drug development and exploratory research projects. At Elan Pharmaceuticals, Dr. Babcock applied genetic, histopathology, and cell biology approaches to better understand the connections between lysosomal dysfunction and Parkinson’s disease. Dr. Babcock then joined BioMarin where he worked on several small molecule drug development projects targeting glycolipid enzymes including glucosylceramide synthase (GCS), ceramide galactosyl transferase(CGT), and acid ceramidase (AC).
© Copyright AceLink Therapeutics. All rights reserved